#### 1 Discontinuity of care and trust in usual physician among patients with systemic lupus

## 2 erythematosus

- 3 Yu Katayama MD, PhD<sup>1</sup>; Yoshia Miyawaki MD, MPH, PhD<sup>1</sup>; Kenta Shidahara MD<sup>1</sup>; Shoichi
- 4 Nawachi MD<sup>1</sup>; Yosuke Asano MD, PhD<sup>1</sup>; Eri Katsuyama MD, PhD<sup>1</sup>; Takayuki Katsuyama MD,
- 5 PhD<sup>1</sup>; Mariko Takano-Narazaki MD, PhD<sup>1</sup>; Yoshinori Matsumoto MD, PhD<sup>1</sup>; Nao Oguro MD,
- 6 PhD<sup>2</sup>; Nobuyuki Yajima MD, MPH, PhD<sup>2, 3, 4</sup>; Yuichi Ishikawa MD<sup>5, 6</sup>; Natsuki Sakurai MD<sup>7</sup>;
- 7 Chiharu Hidekawa MD<sup>7</sup>; Ryusuke Yoshimi MD, PhD<sup>7, 8</sup>; Shigeru Ohno MD, PhD<sup>9</sup>; Takanori
- 8 Ichikawa MD PhD<sup>10</sup>; Dai Kishida MD, PhD<sup>10</sup>; Yasuhiro Shimojima MD, PhD<sup>10</sup>; Ken-ei Sada
- 9 MD, PhD<sup>1, 11</sup>; Jun Wada MD, PhD<sup>1</sup>; David H Thom MD, PhD<sup>12</sup>; Noriaki Kurita MD, PhD<sup>13, 14</sup>
- 10

11	1.	Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama
12		University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
13		Okayama, Japan
14	2.	Division of Rheumatology, Department of Medicine, Showa University School of
15		Medicine, Tokyo, Japan
16	3.	Center for Innovative Research for Communities and Clinical Excellence, Fukushima
17		Medical University, Fukushima, Japan
18	4.	Department of Healthcare Epidemiology, School of Public Health in the Graduate School
19		of Medicine, Kyoto University, Kyoto, Japan
20	5.	The First Department of Internal Medicine, School of Medicine, University of
21		Occupational and Environmental Health, Kitakyushu, Japan
22	6.	Graduate School of Health Innovation, Kanagawa University of Human Services,

23 Kawasaki, Kanagawa, Japan

24	7.	Department of Stem Cell and Immune Regulation, Yokohama City University Graduate
25		School of Medicine, Yokohama, Japan
26	8.	Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
27	9.	Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama,
28		Japan
29	10.	Department of Medicine (Neurology and Rheumatology), Shinshu University School of
30		Medicine, Matsumoto, Japan
31	11.	Department of Clinical Epidemiology, Kochi Medical School, Nankoku, Japan
32	12.	Department of Medicine, Stanford University School of Medicine, Palo Alto, California,
33		USA
34	13.	Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical
35		University, Fukushima, Japan
36	14.	Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),
37		Fukushima Medical University Hospital, Fukushima, Japan
38		
39	Corre	sponding Author: Yoshia Miyawaki, MD, MPH, PhD, Department of Nephrology,
40	Rheum	natology, Endocrinology and Metabolism, Okayama University Graduate School of
41	Medic	ine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-
42	8558, .	Japan.
43	E-mail	: pebe1a85@okayama-u.ac.jp
44		
45	Word	counts: 2279 words
46		
47		

# 48 Key Points

49	Question Is the number of outpatient visits with a covering rheumatologist associated with the
50	loss of trust in usual rheumatologist in patients with systemic lupus erythematosus (SLE)?
51	Findings This multicenter cross-sectional study which included 421 patients with SLE revealed
52	that the number of outpatient visits with a covering rheumatologist in the past year was
53	associated with lower levels of trust in the usual rheumatologist.
54	Meaning This study alerts us about the need to prepare for the possible adverse effects of
55	unavoidable outpatient coverage.
56	
57	
58	Abstract
59	Importance:
60	Patient trust plays a central role in the patient-physician relationship; however, the impact of
61	outpatient visits with a covering physician (covered visits) on the level of trust in usual physician
62	among patients with chronic conditions is unknown.
63	
64	Objective:
65	To determine whether the number of outpatient visits with a covering rheumatologist is
66	associated with patient trust in the usual rheumatologist.
67	
68	Design:
69	Cross-sectional study.

## 71 Setting:

- 72 This study used data from the TRUMP<sup>2</sup>-SLE project conducted at five academic medical centers
- in Japan.
- 74

### 75 **Participants:**

- 76 The participants were Japanese adults with systemic lupus erythematosus who met the 1997
- revised classification criteria of the American College of Rheumatology.
- 78 The enrollment period was February 2020 to October 2021.
- 79

### 80 Exposure:

- 81 Outpatient visits with a covering rheumatologist in the past year.
- 82

### 83 Main Outcomes and Measures:

84 The main outcome was patient trust in their usual rheumatologist, assessed using the 11-item

**35** Japanese version of the modified Trust in Physician Scale (range 0–100). A general linear model

86 with cluster robust variance estimation was used to evaluate the association between the number

87 of outpatient visits with a covering rheumatologist and the patient's trust in their usual

88 rheumatologist.

- 89
- 90 **Results:**

91 Of the 515 enrolled participants, 421 patients with systemic lupus erythematosus were included92 in our analyses.

93 The median age was 47.0 years, and 87.2% were women. Thirty-nine usual rheumatologists

94 participated in this study. Patients were divided into groups according to the number of

95	outpatient visits	with a covering	rheumatologis	t in the past yea	r as follows: no	visits (59.9%;
----	-------------------	-----------------	---------------	-------------------	------------------	----------------

- 96 reference group), one to three visits (24.2%; low-frequency group), and four or more visits
- 97 (15.9%; high-frequency group). The median Trust in Physician Scale score was 81.8
- 98 (interquartile range 72.7–93.2). Both the low-frequency and high-frequency groups exhibited
- 99 lower trust in their usual rheumatologist (mean difference: -3.03 [95% confidence interval -5.93
- 100 to -0.80], -4.17 [95% confidence interval -7.77 to -0.58, respectively]).

101

## 102 Conclusions and Relevance:

103 This study revealed that the number of outpatient visits with a covering rheumatologist was

104 associated with lower trust in a patient's usual rheumatologist. Further research is needed to

address the potential adverse effects of physician coverage on trust in patient's usual

106 rheumatologist.

107

## 109 Introduction

110 Discontinuity of care is a critical process with the potential to adversely affect the quality of 111 patient care. For example, discontinuity of care has been associated with more avoidable hospitalizations and a higher number of procedures.<sup>1,2</sup> While significant attention has been 112 directed toward inpatient handovers<sup>3</sup> and transitions related to year-end resident changeovers,<sup>4,5</sup> 113 114 the impact of temporary outpatient physician coverage remains an understudied clinical question. 115 The necessity for coverage of outpatient care, in the absence of the usual physician is a common 116 and unavoidable occurrence,<sup>6</sup> due to factors such as continuing medical education, maternity leave, or unexpected absenteeism caused by illness.<sup>7</sup> Acting as a surrogate during the usual 117 physician's absence,<sup>8</sup> the covering physician assumes identical responsibilities to those of the 118 primary physician.<sup>9</sup> 119 120 Systemic lupus erythematosus (SLE), characterized by multiple organ damage, requires life-long 121 outpatient visits to mitigate functional disability and optimize quality of life. Maintaining a good 122 physician-patient therapeutic relationship is important because outpatient rheumatologists are 123 required to evaluate patients with SLE through laboratory testing and adjust complex 124 medications based on changes in their disease activity. Trust in the primary rheumatologist is central to this therapeutic relationship,<sup>10</sup> and among patients with SLE, trust is associated with 125 126 excellent medication adherence.<sup>11</sup> 127 When a patient's visit requires coverage by another rheumatologist, the covering rheumatologist 128 is expected to maintain the same quality of care. However, the course of SLE may not be static, 129 and the covering rheumatologist may be forced to make decisions about prescriptions and testing in the absence of an established relationship with the patient.<sup>12</sup> When a patient with SLE 130 131 experiences an unsatisfactory visit with a covering rheumatologist, it may erode their trust in 132 their primary rheumatologist. However, although the association between trust and discontinuity

133	of care has been examined primarily in European and US primary care settings, the results from
134	quantitative studies have been mixed, <sup>13</sup> <sup>14</sup> and few studies have focused on the discontinuity
135	associated with outpatient physician coverage within the same department.
136	The aim of this study was to examine the association between the number of outpatient
137	rheumatologist coverage by colleagues within the same department and patient trust in the
138	primary rheumatologist among Japanese patients with SLE using data from the Trust
139	Measurement for Physicians and Patients with SLE (TRUMP <sup>2</sup> -SLE) project, a multicenter cross-
140	sectional study.
141	
142	Methods
143	Study design and subjects
144	This was a cross-sectional study using baseline data from the TRUMP <sup>2</sup> -SLE study, a multicenter
145	cohort study currently conducted at five academic medical centers (Showa University Hospital,
146	Okayama University Hospital, Shinshu University Hospital, Yokohama City University Hospital,
147	Yokohama City University Medical Center). Patients $\geq 20$ years old who met the revised criteria
148	in 1997 for the classification of SLE by the American College of Rheumatology (ACR) were
149	included. <sup>15</sup> Patients who were seen by their usual rheumatologist for the first time were excluded.
150	All patients provided informed consent prior to enrollment. The patients were consecutively
151	recruited between February 2020 and October 2021.
152	
153	Exposure
154	Exposure in the present study was defined as the patient-reported number of outpatient visits by
155	a covering rheumatologist (NVCs) in the past year. A covering rheumatologist was defined as
156	one in the same facility other than the usual rheumatologist. Based on frequency, the NVCs were

157 classified into three categories: (1) no NVCs (2) one to three NVC (low-frequency group), and158 (3) four or more NVCs (high-frequency group).

- 159
- 160 *Outcome*

The outcome of this study was trust in patients' usual rheumatologist, using the Japanese version
of the 11-item modified Trust in Physicians Scale by Thom.<sup>10,16</sup> Each item is rated on a 5-point
Likert scale ranging from 1 (totally disagree) to 5 (totally agree). Then, the four negatively
worded items were reverse coded and the total score of all items was converted to a range of 0 to
100. This scale has demonstrated high internal consistency reliability (Cronbach's alpha
coefficient = 0.91) and criterion-related validity.<sup>10</sup>

- 167
- 168 *Covariates*

169 Based on previous literature and the clinical expertise of rheumatologists, the potential 170 confounders were determined to be as follows: patient age,<sup>17</sup> patient sex,<sup>17</sup> physician age,<sup>18</sup> physician sex,<sup>18</sup> job title,<sup>19</sup> duration of time since diagnosis of SLE,<sup>19</sup> disease activity, organ 171 172 damage, emotional health, the duration of the relationship with their usual rheumatologist 173 (categorized as <1 year, 1-3 years, and 3 years or more) and the number of visits to their usual 174 rheumatologist in the past year (categorized as one to three times, four to six times, and seven times or more).<sup>10,18</sup> As there are only full professor and associate professor job titles in Japan that 175 176 contains the Kanji character 'kyouju', meaning professor in English, and health information from 177 an authority is more likely to be trusted, the job titles were divided into two groups: associate professor or higher and lecturer or lower.<sup>19</sup> Disease activity was determined by the usual 178 179 physician using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). 180 Organ damage was determined by the Systemic Lupus Erythematosus International Cooperative

181 Clinic/American College of Rheumatology Disability Index (SDI). Emotional health was
182 determined by the LupusPRO domain and was converted to a 0–100-point score.<sup>20</sup> Higher
183 emotional health scores indicated better emotional functioning and role emotional.

184

185 *Statistical analysis* 

186 Patient characteristics were summarized separately by NVCs with continuous variables as 187 median and interquartile range (IQR) and categorical variables as frequencies and percentages. A 188 general linear model was fit to examine the association between NVCs and the trust in the usual 189 rheumatologist. All the above-mentioned covariates were entered into the model. In addition, to 190 examine the possibility that the duration of the relationship with their usual physician may 191 modify the association between NVCs and trust in the physician, their product terms were 192 entered into the model. The presence of the interaction was assessed using the Wald test. Next, a 193 logistic regression model was fit with all the above-mentioned covariates as explanatory 194 variables to explore factors associated with high-frequency NVCs. In both of the models, cluster-195 robust variance estimation was used with each usual rheumatologist as a cluster unit to address the possibility of outcome similarity (i.e., clustering) for the same usual rheumatologist.<sup>21</sup> 196 197 Multiple imputation with chained equations was used to address missing data, assuming that the data were missing at random.<sup>22</sup> All missing values were multiply-imputed 100 times in the 198 imputation process. These estimates were combined using Rubin's rule.<sup>22</sup> All analyses were 199 200 performed using Stata software (version 17.0; Stata Corp, College Station, TX, USA). Statistical 201 significance was set at p < 0.05.

202

203 *Ethical considerations* 

204	This study was conducted in accordance with the Declaration of Helsinki, and the study protocol
205	was approved by the Graduate School of Medical and Dental Sciences of Okayama University
206	and the Okayama University Hospital Ethics Committee (approval number: 2204-020).
207	
208	Results
209	Patient and physician characteristics
210	Of the 515 patients enrolled, 94 were excluded owing to missing or inadequate data on outcomes
211	and exposures, and 421 were ultimately included in the primary analysis. The participant and
212	physician characteristics are shown in Table 1. The median age of the patients was 47 years (IQR
213	36–57), and 367 (87.2%) were female. The median duration of the disease was 12.6 years (IQR
214	6.9–20.3), the median SLEDAI-2K score was 4 (IQR 1–6), and the median SDI was 0 (IQR 0–1).
215	Regarding NVCs, 252 (59.9%) had no visits, 102 (24.2%) had low frequency (1-3 visits), and 67
216	(15.9%) had high frequency ( $\geq$ 4 visits). Patients were seen by a total of 39 usual rheumatologists.
217	The median age of the rheumatologists was 43 years (IQR 38–48), and nine (23.1%) were female.
218	Seven (17.9%) rheumatologists were associate professors or higher in job titles.
219	
220	Association between NVCs and trust in one's usual physician
221	The median Trust in Physician Scale score was 81.8 (IQR 72.7–93.2) and the mean was 81.6
222	(standard deviation 13.3). The distribution of Trust in Physician Scale Score is shown in Figure 1.
223	The association between NVCs and trust in the patient's usual physician is shown in Table 2. In
224	the adjusted model, compared to no NVCs, both low and high frequency NVCs were associated
225	with lower Trust in Physician Scale scores, respectively (adjusted mean difference: -3.01 [95%
226	confidence interval (CI) -5.93 to -0.80] and -4.17 [95% CI -7.77 to -0.58], respectively). We
227	failed to demonstrate evidence of a global interaction between the association between NVCs

and Trust by duration of the relationship with the usual rheumatologist and NVCs (*P* for

- interaction = 0.138).
- 230
- 231
- 232 Factors associated with high frequent NVCs
- 233 The exploratory associations between high-frequency NVCs and covariates are shown in Table 3.
- Greater organ damage (per 1 point higher SDI: aOR 1.27, 95% CI 1.06–1.52) and more frequent
- visits to the usual physician (one to three times vs. four to six times: aOR 3.94, 95% CI 1.48–
- 236 10.48 / one to three times vs. seven or more times: aOR 3.86, 95%CI 1.46–10.16) was positively
- associated with a high frequency of NVCs. On the other hand, better emotional health (per point
- higher: aOR 0.98, 95% CI 0.97–0.99) and higher disease activity (per 1 point higher SLEDAI-
- 239 2K: aOR 0.90, 95%CI 0.84–0.97) were inversely associated with a high frequency of NVCs.
- 240

### 241 Discussion

The present study showed that more frequent NVCs with a covering rheumatologist were
associated with trust in the usual rheumatologist among patients with SLE. The study found a
higher frequency of NVCs was associated with greater organ damage, lower emotional health,
and greater number of visits to the usual rheumatologist in the past year.

Few studies have investigated the effects of outpatient visits with a covering physician on the patient relationship with their usual physician among patients with a chronic disease. However, some studies have helped us to understand the findings of our study. First, rheumatologists can understand the possible mechanisms of the loss of trust with increased NVCs by revisiting the level of trust in their physicians. For example, if the usual rheumatologist's planned care (e.g., performing laboratory tests and explaining their results, or changing the dosage or class of

252 medications) is not communicated to a covering rheumatologist, the patient may feel that the rheumatologists' words and actions are not credible.<sup>23</sup> On the other hand, a covering 253 254 rheumatologist may be hesitant to change medications or order additional testing, preferring to 255 defer to the patient's usual rheumatologist, which could result in a delayed response to changes 256 in the patient with SLE. In addition, if changes in care are not communicated clearly to the usual 257 rheumatologist, the patient may feel the usual rheumatologist is less informed and therefore less 258 capable of providing the best care. The finding that patients with lower emotional health due to 259 depression and/or anxiety are due to those patients requesting visits more urgently than can be 260 scheduled with their usual rheumatologist. 261 The clinical implications of this study are noteworthy. First, rheumatologists need to be aware of 262 the magnitude and meanings of frequent NVCs on the patients' trust in their usual 263 rheumatologists. The magnitude of the 4.17-point lowering of trust scores associated with high 264 frequency ( $\geq$ 4 times/year) NVCs is equivalent to the magnitude (4.30 points) of the impact of 265 past misdiagnosis experiences on trust lowering in the current usual physicians.<sup>10</sup> Second, 266 rheumatologists need to establish preventive measures against loss of trust resulting from physician coverage. For example, as in the case of computerized tools,<sup>24</sup> medical facilities would 267 268 be encouraged to implement a semi-automatic system for handovers of planned laboratory 269 testing, patient explanations, and prescriptions to a covering physician. Alternatively, they could 270 also consider operating an electronic record or a card to be shared whenever any change in 271 patient care occur.<sup>6</sup> More fundamentally, a system that prevents physician coverage would be 272 ideal. For example, if a rheumatologist takes a day off in advance, a patient scheduled to visit on 273 that day should be notified beforehand to change their appointment date or accept an 274 examination by a covering rheumatologist, thereby avoiding patient surprise or disappointment 275 when they enter an examination room and meets an unfamiliar physician.

276 This study had several strengths worth mentioning. First, this was a multicenter study; Therefore, 277 the observed effects of rheumatologists' NVCs on patients' trust are generalizable to similar 278 academic medical centers, instead of reflecting the specific medical structure of a particular 279 institution's department. Second, we adjusted for the physician-level clustering of trust with 280 appropriate multilevel analyses by merging data both from usual rheumatologists and from a large number of their patients.<sup>21</sup> As a result, the observed association between rheumatologists' 281 282 NVCs and trust was not reflective of a particular rheumatologist's behavior.<sup>19</sup> Third, the 283 racial/ethnic homogeneity means that race/ethnicity is not a complicating factor.<sup>25</sup> 284 Several limitations should be noticed in this study. First, the possibility of reverse causation 285 cannot be excluded because of the cross-sectional study design. Some patients may have asked to 286 see a covering rheumatologist because they had less trust in their usual rheumatologist. Second, 287 we were unable to survey the reasons for the physician coverage. In addition to the usual 288 rheumatologist's reasons for arranging coverage, patients may have visited another 289 rheumatologist on a day other than the day of their appointments for patient-related reasons. For 290 example, patients may have rescheduled their appointments on a day when their rheumatologists 291 were not available, or they may have visited another rheumatologist because of unexpected 292 illness. Third, the generalizability of the findings of this study, which were conducted at 293 academic medical centers affiliated with many rheumatologists, may be limited. For example, in 294 the rheumatology departments of city hospitals or private clinics, where only one rheumatologist 295 is often affiliated, rheumatologists must rely on non-rheumatology colleagues or locum tenens for their coverage.<sup>7 26</sup> 296

In conclusion, frequent outpatient NVCs by a covering rheumatologist were associated with alower trust in the using rheumatologist among patients with SLE. Given that occasional time off

- is sometimes required to sustain a medical practice without burnout, this study alerts us about the
- 300 need to prepare for possible adverse effects of unavoidable outpatient coverage.

#### 302 Acknowledgment

- **303** Author Contributions: Dr Katayama and Kurita had full access to all of the data in the study
- and take responsibility for the integrity of the data and the accuracy of the data analysis.
- 305 *Concept and design*: Katayama, Miyawaki, Kurita.
- 306 *Acquisition, analysis, or interpretation of data*: All authors.
- 307 *Drafting of the manuscript*: Katayama, Miyawaki, Kurita.
- 308 *Critical revision of the manuscript for important intellectual content:* All authors. *Statistical*
- 309 *analysis*: Katayama, Miyawaki, Kurita.
- 310 *Obtained funding*: Y.Matsumoto, Kurita
- 311 Administrative, technical, or material support: Katayama, Miyawaki, Yajima, Yoshimi,
- 312 Shimojima, Sada, Kurita.
- 313 *Supervision*: Miyawaki, Yajima, Yoshimi, Shimojima, Sada, Thom, Kurita.

314 Conflict of Interest Disclosures: Dr Kurita reported receiving grants from the Japan Society for

- the Promotion of Science, consulting fees from GlaxoSmithKline K.K., and payments for
- 316 speaking at and participating in educational events from Chugai Pharmaceutical Co, Ltd, Sanofi
- 317 K.K., Mitsubishi Tanabe Pharma Corporation, and the Japan College of Rheumatology. Dr Sada
- 318 reported receiving a research grant from Pfizer Inc and a payment for speaking at and
- 319 participating in educational events from GlaxoSmithKline K.K. Dr Wada reported receiving
- 320 speaker honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kyowa
- 321 Kirin, Novo Nordisk, and Mitsubishi Tanabe, and receives grant support from Bayer, Chugai,
- 322 Kyowa Kirin, Otsuka, Shionogi, Sumitomo, and Mitsubishi Tanabe. Dr Matsumoto reported
- 323 receiving grants from Asahi Kasei Pharma, Taisho and AbbVie, receives speaker honoraria from
- 324 Astra Zeneca, Asahi Kasei Pharma, GlaxoSmithKline and Pfizer and receives a payment for
- 325 participating in educational events from GlaxoSmithKline.

326	Fund	ing/Support: This study was supported by JSPS KAKENHI Grant Numbers 19KT0021 (N.
327	K.) ar	nd 22K19690 (N. K.).
328	Role	of the Funder/Sponsor: The funder had no role in the study design, analyses,
329	interp	retation of the data, writing of the manuscript, or the decision to submit it for publication.
330	Data	Sharing Statement: The dataset analyzed in this paper is available from the corresponding
331	autho	r on reasonable request.
332	Addit	tional Contributions: The authors are grateful to all collaborators in the TRUMP <sup>2</sup> -SLE
333	projec	xt.
334		
335 336	Refer	rences
337	1.	Hussey PS, Schneider EC, Rudin RS, Fox DS, Lai J, Pollack CE. Continuity and the
338		costs of care for chronic disease. JAMA Intern Med. 2014;174(5):742-748.
339	2.	Romano MJ, Segal JB, Pollack CE. The Association Between Continuity of Care and the
340		Overuse of Medical Procedures. JAMA Intern Med. 2015;175(7):1148-1154.
341	3.	Horwitz LI, Moin T, Krumholz HM, Wang L, Bradley EH. Consequences of inadequate
342		sign-out for patient care. Arch Intern Med. 2008;168(16):1755-1760.
343	4.	Young JQ, Ranji SR, Wachter RM, Lee CM, Niehaus B, Auerbach AD. "July effect":
344		impact of the academic year-end changeover on patient outcomes: a systematic review.
345		Ann Intern Med. 2011;155(5):309-315.
346	5.	Young JQ, Wachter RM. Academic year-end transfers of outpatients from outgoing to
347		incoming residents: an unaddressed patient safety issue. Jama. 2009;302(12):1327-1329.
348	6.	Anderson J, Kels BD, Grant-Kels JM. Ethical considerations in alleged dermatologic
349		malpractice. Clin Dermatol. 2012;30(2):174-180.

- 350 7. Maniscalco MM. A physician's guide to working as a locum tenens. *J Am Board Fam*351 *Pract.* 2003;16(3):242-245.
- 8. Becker WG. The covering physician. *J Am Med Dir Assoc.* 2008;9(9):687-688.
- 353 9. McQuoid-Mason DJ. 'Covering doctors' standing in for unavailable colleagues: What is
- 354 the legal position? *S Afr Med J*. 2017;108(1):19-21.
- 355 10. Suzuki R, Yajima N, Sakurai K, et al. Association of Patients' Past Misdiagnosis
- 356 Experiences with Trust in Their Current Physician Among Japanese Adults. *J Gen Intern* 357 *Med.* 2022;37(5):1115-1121.
- 358 11. Kurita N, Oguro N, Miyawaki Y, et al. Trust in the attending rheumatologist, health-
- related hope and medication adherence among Japanese systemic lupus erythematosus

360 patients. *Rheumatology (Oxford)*. 2023;62(6):2147-2153.

- 361 12. Fulton J. Opioids, pain, and personality: the story of a substitute physician. *Can Fam*362 *Physician*. 2011;57(3):271-272.
- 363 13. Mainous AG, 3rd, Baker R, Love MM, Gray DP, Gill JM. Continuity of care and trust in
- 364 one's physician: evidence from primary care in the United States and the United Kingdom.
  365 *Fam Med.* 2001;33(1):22-27.
- 366 14. O'Malley AS, Sheppard VB, Schwartz M, Mandelblatt J. The role of trust in use of
- 367 preventive services among low-income African-American women. *Prev Med.*
- **368** 2004;38(6):777-785.
- 369 15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the
- 370 classification of systemic lupus erythematosus. *Arthritis Rheum*. 1997;40(9):1725.

371	16.	Thom DH, Ribisl KM, Stewart AL, Luke DA. Further validation and reliability testing of
372		the Trust in Physician Scale. The Stanford Trust Study Physicians. Med Care.
373		1999;37(5):510-517.
374	17.	Li C, Khan MM. Public trust in physicians: empirical analysis of patient-related factors
375		affecting trust in physicians in China. BMC Prim Care. 2022;23(1):217.
376	18.	Fiscella K, Meldrum S, Franks P, et al. Patient trust: is it related to patient-centered
377		behavior of primary care physicians? Med Care. 2004;42(11):1049-1055.
378	19.	Oguro N, Yajima N, Ishikawa Y, et al. Effect of Attending Rheumatologists' Big 5
379		Personality Traits on Patient Trust in Patients With Systemic Lupus Erythematosus: The
380		TRUMP2-SLE Project. J Rheumatol. 2024;51(2):168-175.
381	20.	Inoue M, Shiozawa K, Yoshihara R, et al. The Japanese LupusPRO: A cross-cultural
382		validation of an outcome measure for lupus. Lupus. 2017;26(8):849-856.
383	21.	Cameron AC, Miller DL. A practitioner's guide to cluster-robust inference. Journal of
384		human resources. 2015;50(2):317-372.
385	22.	Austin PC, White IR, Lee DS, van Buuren S. Missing Data in Clinical Research: A
386		Tutorial on Multiple Imputation. Can J Cardiol. 2021;37(9):1322-1331.
387	23.	Pearson SD, Raeke LH. Patients' trust in physicians: many theories, few measures, and
388		little data. J Gen Intern Med. 2000;15(7):509-513.
389	24.	Flanagan ME, Patterson ES, Frankel RM, Doebbeling BN. Evaluation of a physician
390		informatics tool to improve patient handoffs. J Am Med Inform Assoc. 2009;16(4):509-
391		515.
392	25.	Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR. Race and trust in the

health care system. *Public Health Rep.* 2003;118(4):358-365.

- 394 26. Inoue K, Matsumoto M, Igarashi M. Short term locum tenens for rural practice: a trial of
- a Japanese medical school. *Aust J Rural Health*. 2002;10(2):80-86.



## **397** Figure 1. The distribution of Trust in Physician Scale Score

398

399 The median Trust in Physician Scale score was 81.8 (IQR 72.7–93.2) and the mean was 81.6 (standard deviation 13.3).

# 401 **Table 1**. Patient and physician characteristics

Patient characteristics					
n=421	Total	0	1 to 3	4 or more	Missing, n
		N=252	N=102	N=67	
Patient age median (IOR)	47.0	47.0	42.0	51.0	0
Tutione ugo, moutum (IQIC)	atient age, median (IQR) $47.0$ $47.0$ $42.0$ (36.0-57.0)(36.0-59.0)(34.8-50.0)atient age, female $r_{1}(0)$ 36721895	(41.0-63.0)	0		
Patient sex female n (%)	367	218	95	54	0
Patient sex, female n (%)	(87.2%)	(86.5%)	(93.1%)	(80.6%)	0
SLEDAI-2K score, median	4.0	4.0	4.0	2.0	0
(IQR)	(1.0-6.0)	(2.0-6.0)	(2.0-6.0)	(0.0-6.0)	0
SDI score median (IOP)	0.0	0.0	0.0	1.0	0
SDI score, median (IQR)	(0.0-1.0)	(0.0-1.0)	(0.0-1.0)	(0.0-2.0)	0
Disease duration, year, median	12.6	12.6	9.3	17.5	5
(IQR)	(6.9-20.3)	(7.3-18.6)	(6.3-18.6)	(9.7-29.2)	5
Emotional health domain	79.2	79.2	79.2	66.7	63
score, median (IQR)	(54.2-91.7)	(62.5-91.7)	(54.2-87.5)	(33.3-91.7)	05
Duration of rheumatologist-					12
patient relationship, n (%)					12
< 1 year	69	36	21	12	
< 1 year	(16.4)	(14.3%)	(20.6%)	12 (17.9%)	
1 to $2$ years	76	46	15	15	
1 to 5 years	(18.1%)	(18.3%)	(14.7%)	(22.4%)	
2 1/20112 01 12012	264	163	62	39	
5 years of more	(62.7%)	(64.7%)	(60.8%)	(58.2%)	
Number of visits to usual					0
rheumatologist, n (%)					9
1 to 2 times	52	33	15	4	
1 to 5 times	(12.4%)	(13.1%)	(14.7%)	(6.0%)	
A to 6 times	210	132	44	34	
4 to o times	(49.9%)	(52.4%)	(43.1%)	(50.7%)	
7 times on mono	150	82	41	27	
/ umes or more	(35.6%)	(32.5%)	(40.2%)	(40.3%)	

Rheumatologist characteristics, n=39	Total	
Rheumatologist age, median (IQR)	43.0 (38.0-48.0)	
Rheumatologist sex, female, n (%)	9 (23.1)	
Job title, n (%)		
Lecturer or lower	32 (82.1)	
Associated professor or higher	7 (17.9)	

402 IQR; interquartile range NVC; Number of outpatient visits to covering rheumatologist

403 SLEDAI-2K; Systemic Lupus Erythematosus Disease Activity Index 2000

404 SDI; Systemic Lupus Erythematosus International Cooperative Clinic/ American College of Rheumatology Disability Index

## 406 Table 2. The association between NVCs and trust in one's usual rheumatologist

	Crude		Adjusted		
The number of visits to covering rheumatologist	β coefficient [95%CI]	P-value	β coefficient [95%CI]	P-value	
No visit	Reference		Reference		
1 to 3 visits	-2.53 [-5.51 to 0.45]	0.094	-3.01 [-5.93 to -0.80]	0.044	
4 visits or more	-5.84 [-9.54 to -2.14]	0.003	-4.17 [-7.77 to -0.58]	0.024	

407

- 408 NVC; Number of outpatient visits to a covering rheumatologist
- 409 General linear models with cluster-robust variance with usual rheumatologists as the unit were fit to address the clustering of
- 410 outcomes by the rheumatologists.
- 411 Adjusted models included patient age, sex, rheumatologist age, sex, job title, disease duration, SLEDAI, SDI, emotional health,
- 412 duration of rheumatologist-patient relationship, and number of visits to their usual rheumatologist

	Odds ratio (95%CI)	P-value
Patient age, per 1-yr higher	1.01 (0.99-1.02)	0.551
Patient sex, female vs male	0.55 (0.24-1.25)	0.153
Rheumatologist age, per 1-yr higher	1.03 (0.95-1.11)	0.512
Rheumatologist sex, female vs male	0.77 (0.24-2.48)	0.660
SLEDAI-2K, per 1-pt higher	0.90 (0.84-0.97)	0.004
SDI, per 1-pt higher	1.27 (1.06-1.52)	0.008
Disease duration, per 1-yr higher	1.03 (0.99-1.07)	0.081
lob title, associated professor or higher vs lecturer or lower	1.34 (0.71-2.53)	0.366
Emotional health, per 1-pt higher	0.98 (0.97-0.99)	0.004
Duration of rheumatologist-patient relationship		
< 1 year	Reference	
1 to 3 years	0.63 (0.19-2.04)	0.436
3 years or more	0.41 (0.15-1.11)	0.081
Number of visits to usual rheumatologist		

414 **Table 3.** Patient and usual rheumatologist factors associated with high frequent number ( $\geq 4$  times/year) of outpatient visits covering

1 to 3 times

Reference

	4 to 6 times	3.94 (1.48-10.48)	0.006
	7 times or more	3.86 (1.46-10.16)	0.006
415	NVC; Number of outpatient visits to covering rheumatologist	SLEDAI-2K; Systemic Lupus Erythematosus Disease	e Activity Index
416	2000		
417	SDI; Systemic Lupus Erythematosus International Cooperative Clinic/ American College of Rheumatology Disability Index		
418	Logistic regression model with cluster-robust variance with their usual rheumatologists as the unit was fit to address the clustering of		
419	outcomes by the rheumatologists.		
420	All variables described in the table were entered into the mode	el.	
421			